Quarterly ResultAug 6, 2026, 08:09 AM
MBX Biosciences Q2 Net Loss $37.1M; Cash $418.6M; MBX 4291 Data On Track
AI Summary
MBX Biosciences reported a net loss of $37.1 million for the second quarter of 2026, an increase from $19.4 million in the same period last year, driven by higher R&D and G&A expenses. Despite the increased loss, the company maintains a strong cash position of $418.6 million, projected to fund operations into 2029. Key corporate highlights include the recruitment for the Phase 3 trial of canvuparatide, positive initial Phase 1 data for MBX 4291 in obesity, and the nomination of new obesity drug candidates MBX 6180 and MBX 5765, alongside executive leadership changes.
Key Highlights
- Net loss for Q2 2026 was $37.1 million, compared to $19.4 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $418.6 million as of June 30, 2026, expected to fund operations into 2029.
- Research and development expenses increased to $31.0 million in Q2 2026 from $17.7 million in Q2 2025.
- General and administrative expenses rose to $9.9 million in Q2 2026 from $4.1 million in Q2 2025.
- Phase 3 pivotal trial for once-weekly canvuparatide in chronic hypoparathyroidism is now recruiting, on track for Q3 2026 initiation.
- Initial Phase 1 data for MBX 4291 showed mean weight loss of 7% at 8 weeks in the first MAD cohort, with 12-week data on track for Q4 2026.
- MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug, was nominated as a development candidate for obesity.
- Steve Hoerter was appointed Chairman and Chief Executive Officer, and John Smither was appointed Chief Financial Officer.
Price Impact
More from MBX